Published in J Bone Miner Res on April 01, 2007
Building bone to reverse osteoporosis and repair fractures. J Clin Invest (2008) 2.40
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Decreased osteoclastogenesis in serotonin-deficient mice. Proc Natl Acad Sci U S A (2012) 1.84
Dynamic visualization of RANKL and Th17-mediated osteoclast function. J Clin Invest (2013) 1.68
Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord (2010) 1.64
Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep (2014) 1.57
Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab (2012) 1.54
Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther (2007) 1.47
Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? Rheumatol Int (2009) 1.25
Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis (2007) 1.23
Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther (2011) 1.22
Osteoclasts: more than 'bone eaters'. Trends Mol Med (2014) 1.17
Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet (2008) 1.06
Abrogation of Cbl-PI3K interaction increases bone formation and osteoblast proliferation. Calcif Tissue Int (2011) 1.03
Tenofovir-associated bone density loss. Ther Clin Risk Manag (2010) 1.02
An irradiation-altered bone marrow microenvironment impacts anabolic actions of PTH. Endocrinology (2011) 1.01
A novel specialized staging system for cancellous fracture healing, distinct from traditional healing pattern of diaphysis corticalfracture? Int J Clin Exp Med (2015) 0.96
Expression and synthesis of bone morphogenetic proteins by osteoclasts: a possible path to anabolic bone remodeling. J Histochem Cytochem (2008) 0.95
Mechanisms of osteoclast-dependent bone formation. Bonekey Rep (2013) 0.94
M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One (2011) 0.94
Osteoclast activity modulates B-cell development in the bone marrow. Cell Res (2011) 0.92
Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways. J Biol Chem (2013) 0.91
Is bone quality associated with collagen age? Osteoporos Int (2009) 0.91
Genetic ablation of CD68 results in mice with increased bone and dysfunctional osteoclasts. PLoS One (2011) 0.90
Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. J Biol Chem (2012) 0.89
Complex dynamics of osteoclast formation and death in long-term cultures. PLoS One (2008) 0.88
Alendronate treatment promotes bone formation with a less anisotropic microstructure during intramembranous ossification in rats. J Bone Miner Metab (2008) 0.87
Inhibition of osteoclast bone resorption by disrupting vacuolar H+-ATPase a3-B2 subunit interaction. J Biol Chem (2010) 0.87
A new osteopetrosis mutant mouse strain (ntl) with odontoma-like proliferations and lack of tooth roots. Eur J Oral Sci (2009) 0.87
Osteopetrosis with micro-lacunar resorption because of defective integrin organization. Lab Invest (2009) 0.87
Early reversal cells in adult human bone remodeling: osteoblastic nature, catabolic functions and interactions with osteoclasts. Histochem Cell Biol (2016) 0.86
Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos Int (2008) 0.85
Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor. Curr Protein Pept Sci (2012) 0.85
Cell replication in craniofacial periosteum: appositional vs. resorptive sites. J Anat (2011) 0.85
3D superimposition and understanding temporomandibular joint arthritis. Orthod Craniofac Res (2015) 0.84
Bone selective protective effect of a novel bone-seeking estrogen on trabecular bone in ovariectomized rats. Calcif Tissue Int (2013) 0.84
Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol (2008) 0.84
The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbits. Calcif Tissue Int (2013) 0.84
Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength. PLoS One (2011) 0.84
Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption. BMC Musculoskelet Disord (2010) 0.83
Cell interactions in bone tissue engineering. J Cell Mol Med (2009) 0.83
Diagnostic index of three-dimensional osteoarthritic changes in temporomandibular joint condylar morphology. J Med Imaging (Bellingham) (2015) 0.82
The anabolic response to parathyroid hormone is augmented in Rac2 knockout mice. Endocrinology (2008) 0.82
The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int (2008) 0.82
ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats. J Bone Miner Metab (2013) 0.81
Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers. Biomark Cancer (2011) 0.81
Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. Drugs (2015) 0.81
Dwarfism in mice lacking collagen-binding integrins α2β1 and α11β1 is caused by severely diminished IGF-1 levels. J Biol Chem (2011) 0.81
TULA-2, a novel histidine phosphatase, regulates bone remodeling by modulating osteoclast function. Cell Mol Life Sci (2012) 0.81
Prostaglandin E2 acts via bone marrow macrophages to block PTH-stimulated osteoblast differentiation in vitro. Bone (2013) 0.80
Transgenic mice for a tamoxifen-induced, conditional expression of the Cre recombinase in osteoclasts. PLoS One (2012) 0.80
High glucose inhibits receptor activator of nuclear factor‑κB ligand-induced osteoclast differentiation via downregulation of v‑ATPase V0 subunit d2 and dendritic cell‑specific transmembrane protein. Mol Med Rep (2014) 0.80
Semen Astragali Complanati- and Rhizoma Cibotii-enhanced bone formation in osteoporosis rats. BMC Complement Altern Med (2013) 0.80
Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women. Br J Clin Pharmacol (2012) 0.78
Aging, human immunodeficiency virus, and bone health. Clin Interv Aging (2010) 0.78
Serum Amyloid A3 Secreted by Preosteoclasts Inhibits Parathyroid Hormone-stimulated cAMP Signaling in Murine Osteoblasts. J Biol Chem (2015) 0.78
Effect of supplementary zinc on orthodontic tooth movement in a rat model. Dental Press J Orthod (2016) 0.77
Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality. BMC Musculoskelet Disord (2010) 0.77
Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption. J Biol Chem (2014) 0.77
Diagnostic index of 3D osteoarthritic changes in TMJ condylar morphology. Proc SPIE Int Soc Opt Eng (2015) 0.77
Bone balance within a cortical BMU: local controls of bone resorption and formation. PLoS One (2012) 0.76
The cast of clasts: catabolism and vascular invasion during bone growth, repair, and disease by osteoclasts, chondroclasts, and septoclasts. Connect Tissue Res (2016) 0.76
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis. Endocrine (2016) 0.76
3D osteoarthritic changes in TMJ condylar morphology correlates with specific systemic and local biomarkers of disease. Osteoarthritis Cartilage (2014) 0.75
Zinc deficiency negatively affects alkaline phosphatase and the concentration of Ca, Mg and P in rats. Nutr Res Pract (2007) 0.75
The Nuclear Receptor AhR Controls Bone Homeostasis by Regulating Osteoclast Differentiation via the RANK/c-Fos Signaling Axis. J Immunol (2016) 0.75
Hormone-stimulated modulation of endocytic trafficking in osteoclasts. Front Endocrinol (Lausanne) (2012) 0.75
Ethyl-3,4-dihydroxybenzoate with a dual function of induction of osteogenic differentiation and inhibition of osteoclast differentiation for bone tissue engineering. Tissue Eng Part A (2014) 0.75
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. Endocr Rev (2017) 0.75
Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats. J Bone Miner Metab (2015) 0.75
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Multiple genetic loci for bone mineral density and fractures. N Engl J Med (2008) 6.35
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
New sequence variants associated with bone mineral density. Nat Genet (2008) 3.43
Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation (2003) 3.37
Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet (2003) 2.86
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet (2009) 2.58
Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature (2013) 2.55
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation (2005) 2.30
The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum (2007) 2.22
Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet (2011) 2.21
Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab (2009) 2.01
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol (2004) 1.88
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab (2008) 1.79
Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause (2005) 1.77
Segmenting articular cartilage automatically using a voxel classification approach. IEEE Trans Med Imaging (2007) 1.73
Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet (2009) 1.73
Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause (2004) 1.66
Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol (2003) 1.64
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 1.64
Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol (2009) 1.62
Opioid facilitation of rewarding electrical brain stimulation is suppressed in rats with neuropathic pain. Anesthesiology (2011) 1.59
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
Individual differences in acute pain-induced endogenous analgesia predict time to resolution of postoperative pain in the rat. Anesthesiology (2015) 1.52
Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res (2003) 1.52
An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause (2004) 1.49
Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J Bone Miner Res (2007) 1.48
Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. J Clin Endocrinol Metab (2012) 1.44
Intra-operative MRI facilitates tumour resection during trans-sphenoidal surgery for pituitary adenomas. Acta Neurochir (Wien) (2011) 1.43
Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther (2008) 1.43
The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res (2008) 1.38
Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech (2003) 1.34
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res (2008) 1.32
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res (2011) 1.32
Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol (2004) 1.31
Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther (2009) 1.30
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab (2007) 1.26
Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol (2005) 1.26
Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? Clin Biochem (2010) 1.25
Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? Rheumatol Int (2009) 1.25
Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther (2011) 1.22
Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem (2003) 1.21
Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol (2009) 1.19
Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab (2006) 1.19
Pain intensity and duration can be enhanced by prior challenge: initial evidence suggestive of a role of microglial priming. J Pain (2010) 1.19
Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone (2005) 1.17
Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum (2007) 1.17
Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone (2003) 1.16
Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res (2002) 1.14
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol (2009) 1.13
Autosomal dominant osteopetrosis revisited: lessons from recent studies. Eur J Endocrinol (2013) 1.12
Associations between aortic calcification and components of body composition in elderly men. Obesity (Silver Spring) (2006) 1.11
Automatic segmentation of the articular cartilage in knee MRI using a hierarchical multi-class classification scheme. Med Image Comput Comput Assist Interv (2005) 1.10
Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones. Dev Biol (2003) 1.10
The implications of body fat mass and fat distribution for cognitive function in elderly women. Obes Res (2004) 1.09
Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int (2010) 1.09
Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab (2014) 1.09
Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum (2006) 1.08
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation (2004) 1.07
The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study. Osteoporos Int (2005) 1.06
Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res (2011) 1.06
The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res (2004) 1.06
Modifiable determinants of fetal macrosomia: role of lifestyle-related factors. Acta Obstet Gynecol Scand (2008) 1.06
Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum (2004) 1.05
Self-administered heroin and cocaine combinations in the rat: additive reinforcing effects-supra-additive effects on nucleus accumbens extracellular dopamine. Neuropsychopharmacology (2006) 1.03
Fetal growth versus birthweight: the role of placenta versus other determinants. PLoS One (2012) 1.03
Central and peripheral fat mass have contrasting effect on the progression of aortic calcification in postmenopausal women. Eur Heart J (2003) 1.02
Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J Bone Miner Res (2007) 1.02
The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS One (2010) 1.02
Serological identification of fast progressors of structural damage with rheumatoid arthritis. Arthritis Res Ther (2013) 1.02
Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause (2004) 1.01
Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone (2006) 1.01
Newborn body fat: associations with maternal metabolic state and placental size. PLoS One (2013) 1.00
Adiposity-related inflammation: effects of pregnancy. Obesity (Silver Spring) (2013) 0.99
Automated detection of hypoglycemia-induced EEG changes recorded by subcutaneous electrodes in subjects with type 1 diabetes--the brain as a biosensor. Diabetes Res Clin Pract (2010) 0.99
Serological muscle loss biomarkers: an overview of current concepts and future possibilities. J Cachexia Sarcopenia Muscle (2012) 0.99
Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone (2005) 0.99
Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs (2008) 0.98